Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron variant.
Infex Therapeutics’ COV-X program inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such, this new approach is unaffected by changes to coronavirus spike protein that is the focus of current concerns about vaccine effectiveness.
Exciting laboratory results at Infex have…
What can patent data reveal about global progress in green innovation, and what might be achieved in years to come?
Appleyard Lees’ inaugural ‘Inside Green Innovation: Progress Report 2021’, analyses patent filings across several areas of green innovation, including food and agriculture, bioplastics and plastics recycling, and renewable energy storage.
This data-driven report gets behind the rhetoric, to shed light on the state of progress in the development of green technologies. How close are we to finding the technological solutions that will be so important for achieving sustainability?…
AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre (DISC) in Cambridge, UK – a state-of-the-art research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.
The new £1bn facility will include the most advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus on specialised and precision medicines and foster the discovery and development of next generation therapeutics, including nucleotide…
Drawing upon over 30-years’ experience of serving the glycobiology research community - AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.
Glycobiology (the study of the structure, biosynthesis, and biology of carbohydrates) is a complex and dynamic area of research that combines enzymology, molecular and cellular biology, organic chemistry and materials science. Widely acknowledged as critical for both cellular biology and studies of carbohydrate-…
Are you building an innovative and emerging life science or biotechstart-up?Now is your opportunity to accelerate your research and transform it into meaningful value for patients byapplying for an Astellas Future Innovator Prize.Astellas is o ering up to two Future Innovator Prizes for a pioneering science and technology platformthat would be a game-changing approach in Astellas’ interest areas including Blindness & Regeneration,Mitochondria Biology, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas
The award for each Astellas Future Innovator Prize winner will:Cover the…
OXFORD, England, Nov. 18, 2021 /PRNewswire/ -- PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, during an event last week at Seoul Yeouido SHIC tower, Seoul, South Korea.
Through this MOU, PharmaVentures and Shinhan Investment Corp intend to collaborate closely to provide a much broader range of capabilities and services to…
15 start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) programme at Stevenage Bioscience Catalyst (SBC), one of Europe’s most important science parks for life sciences. The course was tailored to give data-focused biotech start-ups the skills they need to get potential new drugs and therapies to market more quickly. It was supported by SBC’s community of biotech leaders who shared their expertise through this unique programme focused on the intersection of data analytics and drug discovery.
The programme was launched to seek out…
Cambridge, UK, 17th November 2021: Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.
Professor Bernd Giebel (PhD) is Professor at the University Duisburg-Essen. Highly experienced in the phenotypic characterisation of rare cells, (hematopoietic stem and progenitor cells), Bernd introduced Nanoparticle Tracking Analysis (NTA) to the scientific community as a quantification and size-measuring method for extracellular vesicles (EV) / exosomes in 2011. In the same year he…
A £375 million investment to improve understanding and treatment for a range of neurodegenerative diseases.Funding includes at least £50 million for motor neurone disease (MND) related research to find a cureNew National Institute for Health Research (NIHR) Motor Neurone Disease Research Unit to attract more innovative research applicationsPeople living with neurodegenerative diseases could live longer, healthier lives due to innovative new research, following a government commitment to invest £375 million over the next 5 years.
At least £50 million will be made available specifically for…
Drawing upon over 30-years’ experience of serving the glycobiology research community - AMSBIO has established a comprehensive portfolio of high-quality reagents including unique ranges of antibodies, lectins, enzymes, assay kits and standards, backed by in-depth technical support.Glycobiology (the study of the structure, biosynthesis, and biology of carbohydrates) is a complex and dynamic area of research that combines enzymology, molecular and cellular biology, organic chemistry and materials science. Widely acknowledged…